Novartis Ag (NVS) 77.33 $NVS
Watch for Novartis to Potentially Rebound After Falling 1.81% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 12:55PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $77.37 to a high of $78.26. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $78.62 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 77.33 (-1.61)
After Yesterday's Decline of 1.81%, Novartis Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 13, 12:53PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $77.37 to a high of $78.26. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $78.62 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 77.33 (-1.61)
Global Cytomegalovirus (HHV-5) Infections Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Novartis, Chimerix, Gilead Sciences - Research and Markets
BusinessWire - Fri Jun 10, 10:31AM CDT
Research and Markets has announced the addition of the "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
NVS: 77.33 (-1.61)
Novartis Reports Positive Data on Biosimilar Candidates
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:19AM CDT
Novartis AG (NVS) announced results from two key studies comparing its proposed biosimilar versions of Amgen's (AMGN) blockbuster drug, Enbrel (etanercept), and Roche's (RHHBY) Mabthera (rituximab) to the reference drugs.
NVS: 77.33 (-1.61)
Novartis highlights long-term safety data of Revolade(R) in adults with chronic immune thrombocytopenia, a rare blood disorder
Globe Newswire - Fri Jun 10, 1:31AM CDT
Novartis International AG / Novartis highlights long-term safety data of Revolade(R) in adults with chronic immune thrombocytopenia, a rare blood disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Novartis presents data showing Jakavi(R) is superior to best available therapy in patients with less advanced polycythemia vera (PV)
Globe Newswire - Fri Jun 10, 1:30AM CDT
Novartis International AG / Novartis presents data showing Jakavi(R) is superior to best available therapy in patients with less advanced polycythemia vera (PV) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 34.74 (-0.55), AMGN: 153.08 (-1.70), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
SmarTrend Watching for Potential Rebound in Shares of Novartis After 1.22% Loss
Comtex SmarTrend(R) - Thu Jun 09, 2:49PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $80.33 to a high of $81.08. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $80.97 on volume of 602,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 77.33 (-1.61)
Novartis Set to Possibly Rebound After Yesterday's Selloff of 1.22%
Comtex SmarTrend(R) - Thu Jun 09, 2:47PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $80.33 to a high of $81.08. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $80.97 on volume of 602,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 77.33 (-1.61)
Global Hairy Cell Leukemia Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: AstraZeneca, MedImmune, Novartis - Research and Markets
BusinessWire - Thu Jun 09, 9:18AM CDT
Research and Markets has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H1 2016" report to their offering.
NVS: 77.33 (-1.61)
Global Insomnia Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Eisai, Evotec, Novartis - Research and Markets
BusinessWire - Thu Jun 09, 9:17AM CDT
Research and Markets has announced the addition of the "Insomnia - Pipeline Review, H1 2016" report to their offering.
NVS: 77.33 (-1.61)
New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
Globe Newswire - Thu Jun 09, 12:15AM CDT
Novartis International AG / New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
Globe Newswire - Wed Jun 08, 3:30PM CDT
Novartis International AG / Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Fragile X Syndrome Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Seaside Therapeutics, Novartis, Alcobra - Research and Markets
BusinessWire - Wed Jun 08, 6:12AM CDT
Research and Markets has announced the addition of the "Fragile X Syndrome Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
NVS: 77.33 (-1.61)
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Globe Newswire - Wed Jun 08, 12:15AM CDT
Novartis International AG / Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Incyte Reports Five-Year Data from Phase III Study on Jakafi
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:45AM CDT
Incyte (INCY) announced five-year data from a phase III study on Jakafi for the treatment of patients with intermediate-2 or high-risk myelofibrosis.
INCY: 80.01 (-0.40), LLY: 73.86 (-0.09), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
Novartis (NVS) Announces Data on Leukemia Drug Tasigna
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:44PM CDT
Novartis AG (NVS) announced results from the Treatment-free Remission (TFR) program on oncology drug, Tasigna.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), NVS: 77.33 (-1.61)
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
PR Newswire - Mon Jun 06, 1:40PM CDT
Novartis today announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared to Tafinlar monotherapy1. The results from the COMBI-d three-year follow-up analysis represent one of the longest survival follow-up studies to date with BRAF mutation-positive advanced melanoma patients. Results are being presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
NVS: 77.33 (-1.61)
Novartis combination therapy Tafinlar(R) + Mekinist(R) demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
Globe Newswire - Mon Jun 06, 1:39PM CDT
Novartis International AG / Novartis combination therapy Tafinlar(R) + Mekinist(R) demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer
PR Newswire - Mon Jun 06, 10:01AM CDT
Novartis today announced new data for multiple investigational and established non-small cell lung cancer (NSCLC) treatments, including results from a pivotal, Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) in patients with BRAF V600E-mutation positive (BRAF V600E+) NSCLC. In the study, patients treated with Tafinlar + Mekinist demonstrated an overall response rate (ORR) of 63% (95% CI, 49%-76%)1. Data were presented during an oral session at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) and also published simultaneously in The Lancet Oncology.
NVS: 77.33 (-1.61)
Watch for Novartis to Potentially Rebound After Falling 1.81% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 12:55PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $77.37 to a high of $78.26. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $78.62 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 77.33 (-1.61)
After Yesterday's Decline of 1.81%, Novartis Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 13, 12:53PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $77.37 to a high of $78.26. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $78.62 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 77.33 (-1.61)
Global Cytomegalovirus (HHV-5) Infections Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Novartis, Chimerix, Gilead Sciences - Research and Markets
BusinessWire - Fri Jun 10, 10:31AM CDT
Research and Markets has announced the addition of the "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
NVS: 77.33 (-1.61)
Novartis Reports Positive Data on Biosimilar Candidates
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:19AM CDT
Novartis AG (NVS) announced results from two key studies comparing its proposed biosimilar versions of Amgen's (AMGN) blockbuster drug, Enbrel (etanercept), and Roche's (RHHBY) Mabthera (rituximab) to the reference drugs.
NVS: 77.33 (-1.61)
Novartis highlights long-term safety data of Revolade(R) in adults with chronic immune thrombocytopenia, a rare blood disorder
Globe Newswire - Fri Jun 10, 1:31AM CDT
Novartis International AG / Novartis highlights long-term safety data of Revolade(R) in adults with chronic immune thrombocytopenia, a rare blood disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Novartis presents data showing Jakavi(R) is superior to best available therapy in patients with less advanced polycythemia vera (PV)
Globe Newswire - Fri Jun 10, 1:30AM CDT
Novartis International AG / Novartis presents data showing Jakavi(R) is superior to best available therapy in patients with less advanced polycythemia vera (PV) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 34.74 (-0.55), AMGN: 153.08 (-1.70), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
SmarTrend Watching for Potential Rebound in Shares of Novartis After 1.22% Loss
Comtex SmarTrend(R) - Thu Jun 09, 2:49PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $80.33 to a high of $81.08. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $80.97 on volume of 602,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 77.33 (-1.61)
Novartis Set to Possibly Rebound After Yesterday's Selloff of 1.22%
Comtex SmarTrend(R) - Thu Jun 09, 2:47PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $80.33 to a high of $81.08. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $80.97 on volume of 602,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 77.33 (-1.61)
Global Hairy Cell Leukemia Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: AstraZeneca, MedImmune, Novartis - Research and Markets
BusinessWire - Thu Jun 09, 9:18AM CDT
Research and Markets has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H1 2016" report to their offering.
NVS: 77.33 (-1.61)
Global Insomnia Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Eisai, Evotec, Novartis - Research and Markets
BusinessWire - Thu Jun 09, 9:17AM CDT
Research and Markets has announced the addition of the "Insomnia - Pipeline Review, H1 2016" report to their offering.
NVS: 77.33 (-1.61)
New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
Globe Newswire - Thu Jun 09, 12:15AM CDT
Novartis International AG / New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
Globe Newswire - Wed Jun 08, 3:30PM CDT
Novartis International AG / Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Fragile X Syndrome Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Seaside Therapeutics, Novartis, Alcobra - Research and Markets
BusinessWire - Wed Jun 08, 6:12AM CDT
Research and Markets has announced the addition of the "Fragile X Syndrome Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
NVS: 77.33 (-1.61)
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Globe Newswire - Wed Jun 08, 12:15AM CDT
Novartis International AG / Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Incyte Reports Five-Year Data from Phase III Study on Jakafi
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:45AM CDT
Incyte (INCY) announced five-year data from a phase III study on Jakafi for the treatment of patients with intermediate-2 or high-risk myelofibrosis.
INCY: 80.01 (-0.40), LLY: 73.86 (-0.09), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
Novartis (NVS) Announces Data on Leukemia Drug Tasigna
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:44PM CDT
Novartis AG (NVS) announced results from the Treatment-free Remission (TFR) program on oncology drug, Tasigna.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), NVS: 77.33 (-1.61)
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
PR Newswire - Mon Jun 06, 1:40PM CDT
Novartis today announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared to Tafinlar monotherapy1. The results from the COMBI-d three-year follow-up analysis represent one of the longest survival follow-up studies to date with BRAF mutation-positive advanced melanoma patients. Results are being presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
NVS: 77.33 (-1.61)
Novartis combination therapy Tafinlar(R) + Mekinist(R) demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
Globe Newswire - Mon Jun 06, 1:39PM CDT
Novartis International AG / Novartis combination therapy Tafinlar(R) + Mekinist(R) demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 77.33 (-1.61)
Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer
PR Newswire - Mon Jun 06, 10:01AM CDT
Novartis today announced new data for multiple investigational and established non-small cell lung cancer (NSCLC) treatments, including results from a pivotal, Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) in patients with BRAF V600E-mutation positive (BRAF V600E+) NSCLC. In the study, patients treated with Tafinlar + Mekinist demonstrated an overall response rate (ORR) of 63% (95% CI, 49%-76%)1. Data were presented during an oral session at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) and also published simultaneously in The Lancet Oncology.
NVS: 77.33 (-1.61)
